I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Zvyaglova, M. Yu.
~ 0
results:
Search for persons
X
Format
Online
Mediatypes
Articles (Online)
OpenAccess-fulltext
Languages
english (5)
russian (4)
Sorted by: Relevance
Sorted by: Year
?
1
Loss of response and frequency of adverse events in patient..:
Knyazev, O. V.
;
Zvyaglova, M. Yu.
;
Kagramanova, A. V.
...
Terapevticheskii arkhiv. 93 (2021) 2 - p. 150-157 , 2021
Link:
https://doi.org/10.26442..
?
2
Pharmacological and clinical feature of rebamipide: new the..:
Zvyaglova, M. Yu.
;
Knyazev, O. V.
;
Parfenov, A. I.
Terapevticheskii arkhiv. 92 (2020) 2 - p. 104-111 , 2020
Link:
https://doi.org/10.26442..
?
3
Evaluation of efficacy and comparative frequency of adverse..:
Knyazev, O V
;
Shkurko, T V
;
Kagramanova, A V
...
Terapevticheskii arkhiv. 91 (2019) 8 - p. 41-46 , 2019
Link:
https://doi.org/10.26442..
?
4
Efficacy and safety of tofacitinib in moderate and severe u..:
O. V. Knyazev
;
A. V. Kagramanova
;
A. A. Lishchinskaya
...
https://www.med-sovet.pro/jour/article/view/6415. , 2021
Link:
https://doi.org/10.21518..
?
5
Loss of response and frequency of adverse events in patient..:
O. V. Knyazev
;
M. Yu. Zvyaglova
;
A. V. Kagramanova
...
https://ter-arkhiv.ru/0040-3660/article/viewFile/64705/47582. , 2021
Link:
https://doi.org/10.26442..
?
6
Efficacy and safety of tofacitinib in moderate and severe u..:
O. Knyazev V
;
A. Kagramanova V
;
A. Lishchinskaya A
...
https://www.med-sovet.pro/jour/article/view/6415/5806. , 2021
Link:
https://www.med-sovet.pr..
?
7
Evaluation of efficacy and comparative frequency of adverse..:
O V Knyazev
;
T V Shkurko
;
A V Kagramanova
...
https://ter-arkhiv.ru/0040-3660/article/viewFile/33603/pdf. , 2019
Link:
https://doi.org/10.26442..
?
8
P192 Frequency of hereditary and acquired thromboembolic co..:
Knyazev, O
;
Lishchinskaia, A
;
Kagramanova, A
...
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S259-S260 , 2021
Link:
https://doi.org/10.1093/..
?
9
P243 Elevated presepsin levels are a marker of sepsis risk ..:
Knyazev, O
;
Kagramanova, A
;
Lishchinskaya, A
...
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S286-S287 , 2021
Link:
https://doi.org/10.1093/..
?
10
P270 Mesenchymal stromal cells contribute to the recovery o..:
Knyazev, O
;
Kagramanova, A V
;
Lishchinskaya, A
...
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S304-S304 , 2021
Link:
https://doi.org/10.1093/..
?
11
DOP77 The effectiveness of combination therapy mesenchymal ..:
Knyazev, O
;
Kagramanova, A
;
Lishchinskaya, A
...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S076-S077 , 2019
Link:
https://doi.org/10.1093/..
?
12
P476 Combined therapy with adalimumab and mesenchymal strom..:
Knyazev, O
;
Kagramanova, A
;
Kulakov, D
..
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S350-S350 , 2019
Link:
https://doi.org/10.1093/..
1-12
